Search

Search Constraints

You searched for: Author/Creator Feldmann, Marc

Search Results

4. Anti-tumour necrosis factor therapy for early-stage Dupuytren's disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial. (June 2022)

5. Balance between activating NKG2D, DNAM‐1, NKp44 and NKp46 and inhibitory CD94/NKG2A receptors determine natural killer degranulation towards rheumatoid arthritis synovial fibroblasts. Issue 4 (August 2014)

8. Could toll-like receptors provide a missing link in chronic inflammation in rheumatoid arthritis? Lessons from a study on human rheumatoid tissue. (12th October 2007)